



Sakura Finetek USA Press Release

January 29, 2021

Sakura Finetek USA launches 2 new antibodies under the Genemed® brand

Contact: Erico von Bueren, Director of Marketing

TORRANCE, CA – Sakura Finetek USA, Inc. today announced the launch of 2 new antibodies, including PRAME (PReferentially expressed Antigen in MELanoma). The anti-PRAME antibody is a useful aid in the differential diagnosis of melanoma versus benign melanocytic lesions, when used in a panel with other antibodies.

“We are excited to announce the continued development and commercial launch of these new and clinically valuable biomarkers. These upcoming antibodies is will be especially useful in dermatopathology where we are seeing significant interest and customer demand”, said George Kennedy, Senior Vice President of Sales and Marketing.

“The addition of these 2 products continue to broaden our portfolio of antibodies available to our customers. And with the addition of trending biomarkers or commercial “Gems” like PRAME, we are always looking to expand our menu with new antibodies we expect to have growing diagnostic value in the future”, stated William Jennings, Senior Product Manager of Advanced Staining.

The 2 new products include:

- Genemed® anti-PRAME Rabbit Monoclonal Antibody [EP461]
- Genemed® anti-E-Cadherin Mouse Monoclonal Antibody [ZM63]

Like the wide range of antibodies launched previously, these 2 new antibodies are provided in 2 formats:

- 1 mL concentrate
- 7 mL ready-to-use



continuous innovation for pathology

About Genemed

The Genemed antibody portfolio offers a broad range of primary antibodies suitable for immunohistochemistry (IHC) on formalin-fixed paraffin embedded tissue specimens. We primarily focus on in vitro diagnostics (IVD), which includes antibodies, detection systems, and ancillary reagents for clinical testing in the histopathology laboratory.

Genemed IHC products offer you innovation that can only come from a company whose focus since 1987 has been geared toward producing diagnostically relevant antibodies for clinical pathology.

About Sakura Finetek, USA, Inc.

With its U.S. office based in Torrance, California, Sakura Finetek is the global leader in advancing cancer diagnostics by providing integrated solutions for anatomic pathology and patient treatment through best-in-class innovation, quality and customer care. With a strategic focus on end-to-end automation, Sakura Finetek continues to lead the industry in the development and commercialization of automated histopathology instrumentation and consumables for anatomic pathology.

Sakura Finetek systems dramatically increase efficiency, standardize results, and enable clinical laboratories to more simply manage their daily workload while significantly impacting patient care. Visit www.sakuraus.com to learn more.

Erico von Bueren
Director of Marketing
Sakura Finetek USA, Inc.
1750 W. 214th St.
Torrance, CA 90501
evonbueren@sakuraus.com

MPRE0062 Rev A